The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global anesthesia endotracheal tubes market exhibited moderate growth during 2015-2020. Looking forward, IMARC Group expects the market to grow at a CAGR of around 5% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
Anesthesia endotracheal tubes (ETTs) refer to flexible catheters used for endotracheal intubation to facilitate artificial breathing and introduce sedating gases. Some of the commonly used anesthesia endotracheal tubes include orotracheal tubes, which are inserted through the nose, and nasotracheal tubes, which are inserted through the mouth into the trachea. They are manufactured using polyvinylchloride (PVC) and are used for introducing oxygen, xenon, sevoflurane and isoflurane. These tubes also protect the lungs from contamination of gastric contents and nasopharyngeal matter. As a result, they find extensive applications for various medical procedures, such as general anesthetic surgeries for traumas or severe illnesses and preventing airway obstruction.
The increasing prevalence of chronic medical ailments across the globe represents one of the key factors driving the growth of the market. Furthermore, the rising geriatric population, which is more susceptible to respiratory diseases and cardiovascular disorders (CVDs), is also driving the market growth. In line with this, as the coronavirus disease (COVID-19) continues to spread across the globe, there has been a significant increase in the demand for anesthesia ETTs in the healthcare centers for conducting airway-related procedures. Additionally, various technological advancements, such as the development of innovative silver-coated ETTs, are acting as other growth-inducing factors. These tubes minimize the risks of hospital-acquired infections in patients that are intubated or mechanically ventilated. Product manufacturers are also developing variants with flexible tips that can easily move through fragile airways with minimal discomfort, which is creating a positive outlook for the market. Other factors, including extensive research and development (R&D) activities, along with improvements in the healthcare infrastructure, are anticipated to drive the market further.
IMARC Group provides an analysis of the key trends in each sub-segment of the global anesthesia endotracheal tubes market report, along with forecasts for growth at the global, regional and country level from 2021-2026. Our report has categorized the market based on region, intubation type, product type and end user.
Breakup by Intubation Type:
Breakup by Product Type:
Breakup by End User:
Breakup by Region:
The report has also analysed the competitive landscape of the market with some of the key players being C. R. Bard Inc. (Becton, Dickinson and Company), ConvaTec Group Plc, Fuji Systems Co. Ltd., GE Healthcare Inc. (General Electric Company), Intersurgical Limited, Medtronic Plc, Neurovision Medical Products Inc., Sewoon Medical Co. Ltd., Smiths Medical Inc. and Teleflex Incorporated.
|Base Year of the Analysis||2020|
|Segment Coverage||Intubation Type, Product Type, End User, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||C. R. Bard Inc. (Becton, Dickinson and Company), ConvaTec Group Plc, Fuji Systems Co. Ltd., GE Healthcare Inc. (General Electric Company), Intersurgical Limited, Medtronic Plc, Neurovision Medical Products Inc., Sewoon Medical Co. Ltd., Smiths Medical Inc. and Teleflex Incorporated|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2299
Five User License: US$ 3399
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at